이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

수술 후 점막 흑색종 재발을 방지하기 위해 니볼루맙 단독 또는 카보잔티닙과 함께 사용

2026년 11월 11일 업데이트: National Cancer Institute (NCI)

절제된 점막 흑색종 환자에서 카보잔티닙을 포함하거나 포함하지 않는 보조제 니볼루맙의 무작위 2상 시험

This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma.

SECONDARY OBJECTIVES:

I. To compare overall survival between the two adjuvant therapies. II. To evaluate the adverse effects in each arm. III. To assess the correlation between PD-L1 expression in tumor cells with survival (recurrence free survival [RFS] and overall survival [OS]).

IV. To evaluate the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), and OS of nivolumab plus cabozantinib in patients who cannot undergo gross total resection of disease or have metastatic disease at baseline.

V. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.

OUTLINE: Patients whose tumor has been fully removed by surgery are randomized to Arm 1 or Arm 2. Patients whose tumor has not been fully removed by surgery or has spread are assigned to Arm 3.

ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and cabozantinib orally (PO) once daily (QD) of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.

ARM 2: Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.

ARM 3: Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo echocardiogram (ECHO) during screening and as clinically indicated throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.

After completion of study treatment, patients are followed up every 3 months until disease progression, and then every 6 months for up to 5 years from registration or until death.

연구 유형

중재적

등록 (추정된)

101

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Auburn, California, 미국, 95602
        • Sutter Auburn Faith Hospital
      • Berkeley, California, 미국, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Fremont, California, 미국, 94538
        • Palo Alto Medical Foundation-Fremont
      • Los Angeles, California, 미국, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, 미국, 90020
        • Keck Medicine of USC Koreatown
      • Los Angeles, California, 미국, 90033
        • Los Angeles General Medical Center
      • Modesto, California, 미국, 95355
        • Memorial Medical Center
      • Newport Beach, California, 미국, 92663
        • USC Norris Oncology/Hematology-Newport Beach
      • Palo Alto, California, 미국, 94304
        • Stanford Cancer Institute Palo Alto
      • Palo Alto, California, 미국, 94301
        • Palo Alto Medical Foundation Health Care
      • Roseville, California, 미국, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, 미국, 95816
        • Sutter Medical Center Sacramento
      • San Francisco, California, 미국, 94158
        • UCSF Medical Center-Mission Bay
      • San Francisco, California, 미국, 94115
        • California Pacific Medical Center-Pacific Campus
      • San Mateo, California, 미국, 94401
        • Mills Health Center
      • Santa Cruz, California, 미국, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Rosa, California, 미국, 95403
        • Sutter Pacific Medical Foundation
      • Sunnyvale, California, 미국, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Vallejo, California, 미국, 94589
        • Sutter Solano Medical Center/Cancer Center
    • Colorado
      • Englewood, Colorado, 미국, 80113
        • The Melanoma and Skin Cancer Institute
    • Florida
      • Aventura, Florida, 미국, 33180
        • UM Sylvester Comprehensive Cancer Center at Aventura
      • Coral Gables, Florida, 미국, 33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach, Florida, 미국, 33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Miami, Florida, 미국, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Plantation, Florida, 미국, 33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
    • Idaho
      • Boise, Idaho, 미국, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, 미국, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, 미국, 83814
        • Kootenai Health - Coeur d'Alene
      • Nampa, Idaho, 미국, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Post Falls, Idaho, 미국, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, 미국, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
    • Illinois
      • Aurora, Illinois, 미국, 60504
        • Rush-Copley Medical Center
      • Centralia, Illinois, 미국, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Danville, Illinois, 미국, 61832
        • Carle at The Riverfront
      • DeKalb, Illinois, 미국, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, 미국, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, 미국, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Effingham, Illinois, 미국, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, 미국, 62401
        • Carle Physician Group-Effingham
      • Geneva, Illinois, 미국, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, 미국, 60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, 미국, 60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Lake Forest, Illinois, 미국, 60045
        • Northwestern Medicine Lake Forest Hospital
      • Mattoon, Illinois, 미국, 61938
        • Carle Physician Group-Mattoon/Charleston
      • O'Fallon, Illinois, 미국, 62269
        • Cancer Care Center of O'Fallon
      • Orland Park, Illinois, 미국, 60462
        • Northwestern Medicine Orland Park
      • Springfield, Illinois, 미국, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, 미국, 62702
        • Springfield Clinic
      • Springfield, Illinois, 미국, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, 미국, 61801
        • Carle Cancer Center
      • Warrenville, Illinois, 미국, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Yorkville, Illinois, 미국, 60560
        • Rush-Copley Healthcare Center
    • Iowa
      • Ames, Iowa, 미국, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, 미국, 50010
        • McFarland Clinic - Ames
      • Ankeny, Iowa, 미국, 50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Boone, Iowa, 미국, 50036
        • McFarland Clinic - Boone
      • Clive, Iowa, 미국, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, 미국, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Jefferson, Iowa, 미국, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, 미국, 50158
        • McFarland Clinic - Marshalltown
      • Waukee, Iowa, 미국, 50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Battle Creek, Michigan, 미국, 49017
        • Bronson Battle Creek
      • Grand Rapids, Michigan, 미국, 49503
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, 미국, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo, Michigan, 미국, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, 미국, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, 미국, 49009
        • Beacon Kalamazoo Cancer Center
      • Muskegon, Michigan, 미국, 49444
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, 미국, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, 미국, 49444
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, 미국, 49677
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, 미국, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Traverse City, Michigan, 미국, 49684
        • Munson Medical Center
      • Wyoming, Michigan, 미국, 49519
        • University of Michigan Health - West
    • Minnesota
      • Burnsville, Minnesota, 미국, 55337
        • Minnesota Oncology - Burnsville
      • Coon Rapids, Minnesota, 미국, 55433
        • Mercy Hospital
      • Edina, Minnesota, 미국, 55435
        • Fairview Southdale Hospital
      • Minneapolis, Minnesota, 미국, 55407
        • Abbott-Northwestern Hospital
      • Robbinsdale, Minnesota, 미국, 55422
        • North Memorial Medical Health Center
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic in Rochester
      • Saint Louis Park, Minnesota, 미국, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, 미국, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, 미국, 55102
        • United Hospital
    • Missouri
      • Farmington, Missouri, 미국, 63640
        • Parkland Health Center - Farmington
      • Sainte Genevieve, Missouri, 미국, 63670
        • Sainte Genevieve County Memorial Hospital
      • St Louis, Missouri, 미국, 63131
        • Missouri Baptist Medical Center
      • Sullivan, Missouri, 미국, 63080
        • Missouri Baptist Sullivan Hospital
    • Montana
      • Anaconda, Montana, 미국, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, 미국, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, 미국, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, 미국, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, 미국, 59901
        • Logan Health Medical Center
      • Missoula, Montana, 미국, 59804
        • Community Medical Center
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • Memorial Sloan Kettering Basking Ridge
    • New York
      • Camillus, New York, 미국, 13031
        • Hematology Oncology Associates of CNY at Camillus
      • East Syracuse, New York, 미국, 13057
        • Hematology Oncology Associates of Central New York-East Syracuse
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering Westchester
      • Lake Success, New York, 미국, 11042
        • Northwell Health/Center for Advanced Medicine
      • Mineola, New York, 미국, 11501
        • NYU Langone Hospital - Long Island
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, 미국, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    • Ohio
      • Centerville, Ohio, 미국, 45459
        • Miami Valley Hospital South
      • Cincinnati, Ohio, 미국, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cleveland, Ohio, 미국, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, 미국, 44109
        • MetroHealth Medical Center
      • Dayton, Ohio, 미국, 45409
        • Miami Valley Hospital
      • Dayton, Ohio, 미국, 45415
        • Miami Valley Hospital North
      • Dayton, Ohio, 미국, 45415
        • Dayton Physician LLC - Englewood
      • Dayton, Ohio, 미국, 45409
        • Premier Blood and Cancer Center
      • Franklin, Ohio, 미국, 45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Greenville, Ohio, 미국, 45331
        • Miami Valley Cancer Care and Infusion
      • Kettering, Ohio, 미국, 45429
        • Kettering Medical Center
      • Troy, Ohio, 미국, 45373
        • Upper Valley Medical Center
    • Oklahoma
      • Lawton, Oklahoma, 미국, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Ontario, Oregon, 미국, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, 미국, 15232
        • UPMC Hillman Cancer Center
      • Willow Grove, Pennsylvania, 미국, 19090
        • Asplundh Cancer Pavilion
    • South Dakota
      • Rapid City, South Dakota, 미국, 57701
        • Rapid City Regional Hospital
      • Sioux Falls, South Dakota, 미국, 57105
        • Avera Cancer Institute
    • Texas
      • Houston, Texas, 미국, 77030
        • UT MD Anderson Cancer Center
    • Virginia
      • Richmond, Virginia, 미국, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, 미국, 23298
        • VCU Massey Comprehensive Cancer Center
    • Wisconsin
      • Eau Claire, Wisconsin, 미국, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Eau Claire, Wisconsin, 미국, 54701
        • HSHS Sacred Heart Hospital
      • Green Bay, Wisconsin, 미국, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, 미국, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • Madison, Wisconsin, 미국, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Madison, Wisconsin, 미국, 53718
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Marshfield, Wisconsin, 미국, 54449
        • Marshfield Medical Center-Marshfield
      • Minocqua, Wisconsin, 미국, 54548
        • Marshfield Medical Center - Minocqua
      • Oconto Falls, Wisconsin, 미국, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Rice Lake, Wisconsin, 미국, 54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, 미국, 53081
        • Saint Vincent Hospital Cancer Center at Sheboygan
      • Stevens Point, Wisconsin, 미국, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Sturgeon Bay, Wisconsin, 미국, 54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Weston, Wisconsin, 미국, 54476
        • Marshfield Medical Center - Weston
    • Ontario
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • Ottawa Hospital and Cancer Center-General Campus
      • Toronto, Ontario, 캐나다, M5G 2M9
        • University Health Network-Princess Margaret Hospital
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Odette Cancer Centre- Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, 캐나다, H3T 1E2
        • Jewish General Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • STEP 0 INCLUSION CRITERIA

  • Histologically proven mucosal melanoma by local pathology

  • Central PD-L1 tumor tissue submission

  • STEP 1 INCLUSION CRITERIA

  • Receipt of the central PD-L1 testing results available

    • Report is required for randomization of resection R0 or R1 patients
    • Testing must be started in Step 0 but results can be reported after registration for resection R2 patients
  • Disease status-Resected R0 or R1 disease patients. Patients eligible for randomization have resected R0 or R1 disease (with negative margins or positive microscopic margins) that must meet one of the following 4 criteria as defined below:

    • Regional lymph node (LN) involvement; OR

    • In-transit metastases/satellite primary disease; OR

    • Single localized, primary disease meeting one of the following site-specific requirements:

      • Head/neck - Sinonasal (including nasopharynx): any primary lesion; Nasal or oral cavity; pT4a or above, given slightly improved OS

        • NOTE: Conjunctival: does not meet the qualification for eligibility
      • Anorectal - any primary lesion

      • Vaginal/cervical - any primary, as they have 5 year OS rates of 5-25%

      • Urinary tract - any primary urethral or bladder tumor

      • Penile

      • Vulvar- American Joint Committee on Cancer (AJCC) cutaneous stage IIB or higher

      • Esophageal/gallbladder - any primary

    • Locoregionally recurrent following prior resection, meeting at least one of the above criteria

    • In addition, patients must have undergone cross-sectional imaging of the brain, chest, abdomen and pelvis with no evidence of distant metastatic disease

  • Disease status-Non-resected R2 or metastatic disease patients

    • Non-resected R2 or metastatic disease that is assessable and measurable radiographically or by physical examination
  • Prior Treatment:

    • No prior systemic checkpoint inhibitor therapy of mucosal melanoma, including in the adjuvant setting, is allowed. Prior adjuvant chemotherapy or interferon is allowed.
    • No other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator. Exceptions may allow for adjuvant no evidence of disease (NED) cancers undergoing hormone based therapy may be eligible pending the other eligibility criteria are met and the principal investigator (PI) affirms the hormonal agent would not change the melanoma response.
    • Any radiation must have completed 28 days prior to randomization and the patient must have adequately recovered from its effects.
    • For resectable patients only: Surgery must have completed 28 days prior to randomization.
    • For resectable patients only: Surgery must have completed no more than 84 days prior to randomization.
  • Not pregnant and not nursing, because this study has an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required

  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Absolute neutrophil count (ANC) >= 1,500/mm^3

  • Platelet count >= 100,000/mm^3

  • Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance (CrCl) >= 50mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

  • Albumin >= 2.8 g/dL

  • Total bilirubin =< 1.5 x upper limit of normal (ULN)

  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)

  • No cardiovascular disease, including:

    • No history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft (CABG) coronary angioplasty, or stenting within 6 months prior to study entry.
    • No history of current class II or higher congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.
    • No refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg despite adequate attempts at anti-hypertensive therapy.
    • No history of myocarditis.
    • No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months.
    • No corrected QT interval by Fridericia's formula (QTcF) > 500 msec. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard.
  • No underlying hematologic issues, including:

    • Congenital bleeding diathesis
    • Gastrointestinal (GI) bleeding requiring intervention within the past 6 months, unless directly related to mucosal melanoma
    • Active hemoptysis within 42 days prior to study enrollment.
    • Active tumor lesions with cavitations or tumor lesions which invade, encase, or abut major blood vessels. The anatomic location and characteristics of primary tumors or metastases as well as the medical history should be carefully reviewed in the selection of subjects for treatment with cabozantinib/placebo.
    • Pulmonary emboli or deep vein thromboses (DVT) that require an active anticoagulation regimen.
    • No known or suspected history of cytopenia (low white blood cell [WBC], hemoglobin or platelet count) of greater than 3 months duration with an unknown cause, myelodysplastic syndrome, or hematologic malignancies.
  • No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of pre-registration (e.g., active symptoms of COVID-19 infection or a post-infectious symptomatic autoimmune syndrome, serious bacterial infections requiring antibiotics).

  • No known or suspected gastrointestinal disorder affecting absorption of oral medications.

  • Comorbid conditions:

    • No active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

    • No history of autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) or non-infectious pneumonitis.

    • No history of severe allergic reactions to an unknown allergen or any components of the study drugs or its excipients.

    • No history of gastrointestinal perforation or abdominal fistula.

    • No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases. Patients with a history of CNS metastasis(s) will be allowed as long as

      • The metastatic site(s) were adequately treated as demonstrated by clinical and radiographic improvement, AND
      • The patient has recovered from the intervention (no residual adverse events > Common Terminology Criteria for Adverse Events [CTCAE] grade 1), AND
      • The patient has remained without occurrence of new or worsening CNS symptoms for a period of 28 days prior to enrollment.
    • No history of seizure or any condition that may increase the patient's seizure risk (e.g., prior cortical stroke, significant brain trauma) within 2 years.

    • No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction.

    • No untreated spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression. Spinal metastases must have completed planned radiation or surgical therapy prior to registration.

  • Concomitant medications:

    • Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 5 days prior to the start of study treatment.
    • Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 5 days prior to the start of study treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm 1 (nivolumab, cabozantinib)

Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • BMS-907351
  • 카보메틱스
  • 코메트릭
  • XL-184
  • XL184
  • 특대형 184

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC

Undergo PET

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • PT
  • 양전자방출단층촬영(시술)

Given IV

다른 이름들:
  • BMS-936558
  • MDX-1106
  • 니보
  • ONO-4538
  • 옵디보
  • CMAB819
  • 니볼루맙 바이오시밀러 CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • 니볼루맙 바이오시밀러 ABP 206
  • BCD-263
  • 니볼루맙 바이오시밀러 BCD-263
  • BMS936558
  • 오노 4538
  • ONO4538

Undergo bone scan

다른 이름들:
  • 뼈 신티그래피

Undergo blood and tissue sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집
활성 비교기: Arm 2 (nivolumab, placebo)

Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC

Undergo PET

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • PT
  • 양전자방출단층촬영(시술)

Given IV

다른 이름들:
  • BMS-936558
  • MDX-1106
  • 니보
  • ONO-4538
  • 옵디보
  • CMAB819
  • 니볼루맙 바이오시밀러 CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • 니볼루맙 바이오시밀러 ABP 206
  • BCD-263
  • 니볼루맙 바이오시밀러 BCD-263
  • BMS936558
  • 오노 4538
  • ONO4538

Undergo bone scan

다른 이름들:
  • 뼈 신티그래피

Undergo blood and tissue sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Given PO

실험적: Arm 3 (nivolumab, cabozantinib)

Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • BMS-907351
  • 카보메틱스
  • 코메트릭
  • XL-184
  • XL184
  • 특대형 184

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC

Undergo PET

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • PT
  • 양전자방출단층촬영(시술)

Given IV

다른 이름들:
  • BMS-936558
  • MDX-1106
  • 니보
  • ONO-4538
  • 옵디보
  • CMAB819
  • 니볼루맙 바이오시밀러 CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • 니볼루맙 바이오시밀러 ABP 206
  • BCD-263
  • 니볼루맙 바이오시밀러 BCD-263
  • BMS936558
  • 오노 4538
  • ONO4538

Undergo bone scan

다른 이름들:
  • 뼈 신티그래피

Undergo blood and tissue sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Recurrence free survival (RFS)
기간: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years

Will evaluate RFS of single agent adjuvant nivolumab plus placebo compared to the combination treatment of adjuvant nivolumab plus cabozantinib in patients with resected mucosal melanoma.

Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Overall survival (OS)
기간: Number of days from registration until death (due to any cause, assessed up to 5 years

Will be evaluated utilizing the Kaplan-Meier (KM) method and, when appropriate, cox proportional hazards models. Median OS is calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model is built to compare arms 1 and 2 with respect to OS.

Number of days from registration until death (due to any cause, assessed up to 5 years
RFS
기간: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years

Median RFS will be calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model will also be built to compare arms 1 and 2 with respect to RFS, with and without stratifying for PD-L1 categorization. For non-resected cohort, If a patient in this group has surgery, their RFS data will be censored at the time of surgery.

Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
Progression free survival
기간: Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years

Will be evaluated in multiple settings utilizing the KM method and, when appropriate, cox proportional hazards models.

Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
Objective response rate (Arm 3)
기간: Up to 5 years

Will assess this endpoint utilizing a two-stage Simon that looks to improve from a rate of 20% to 47%.

Up to 5 years
Duration of response (Arm 3)
기간: Time from the first evidence of response until progression, assessed up to 5 years

A KM analysis is performed to calculate the median duration of response and 95% confidence intervals are constructed.

Time from the first evidence of response until progression, assessed up to 5 years
Incidence of adverse events
기간: Up to 5 years

The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be summarized.

Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Alexander N Shoushtari, Alliance for Clinical Trials in Oncology

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 8월 11일

기본 완료 (추정된)

2027년 7월 15일

연구 완료 (추정된)

2027년 7월 15일

연구 등록 날짜

최초 제출

2021년 11월 5일

QC 기준을 충족하는 최초 제출

2021년 11월 5일

처음 게시됨 (실제)

2021년 11월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI-2021-11794
  • U10CA180821 (미국 NIH 보조금/계약)
  • NCI-2021-11794 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • A091903 (기타 식별자: CTEP)
  • A091903 (기타 식별자: Alliance for Clinical Trials in Oncology)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다